Research analysts covering EUDA Health Holdings.
Recent press releases and 8-K filings for EUDA.
EUDA Health Amends Streeterville Warrant Agreement
EUDA
- EUDA Health Holdings Limited announced a second amendment to its warrant agreement with Streeterville Capital, LLC on January 15, 2026.
- The amendment, dated January 13, 2026, reduced the exercise price of the warrant from US$4.00 per share to US$2.00 per share.
- The minimum closing price required to trigger a forced exercise of the warrant was also reduced from US$6.00 to US$3.00.
- EUDA's CEO, Mr. Alfred Lim, views this as a technical adjustment to align warrant terms with current market conditions and preserve capital structure flexibility, without altering the company's long-term strategy.
Jan 15, 2026, 9:30 PM
EUDA Health Holdings Amends Warrant Terms, Reducing Exercise Price
EUDA
- EUDA Health Holdings Limited and an accredited investor executed a Second Warrant Amendment on January 13, 2026.
- This amendment reduces the warrant exercise price from $4.00 to $2.00 per share.
- It also lowers the minimum Nasdaq closing price for a Forced Exercise from $6.00 to $3.00.
- This follows a First Amendment on December 16, 2025, which previously reduced the exercise price from $6.00 to $4.00 and the Forced Exercise price from $7.50 to $6.00.
Jan 13, 2026, 9:51 PM
EUDA Health Holdings Amends Streeterville Warrant Agreement
EUDA
- EUDA Health Holdings Limited announced on January 7, 2026, an amendment to its warrant agreement with Streeterville Capital, LLC.
- The amendment, entered into on December 16, 2025, reduced the warrant's exercise price from US$6.00 per share to US$4.00 per share.
- Additionally, the minimum closing price required to trigger a "Forced Exercise" was lowered from US$7.50 to US$6.00.
Jan 7, 2026, 1:27 PM
EUDA Health Holdings Launches Stem Cell Platform in China
EUDA
Product Launch
New Projects/Investments
- EUDA Health Holdings Limited launched a nationwide stem cell extraction, cryogenic storage, and clinical delivery platform in China on December 30, 2025.
- The company has partnered with Shenzhen Inno Immune Co., Ltd. and Wuhan Kaien Hospital for this initiative.
- Shenzhen Inno Immune will serve as the primary cell processing and cryogenic storage hub in Southern China, with an initial designed capacity of approximately 50,000 patient cell units.
- Wuhan Kaien Hospital will function as the Central China clinical and longevity flagship, with a planned capacity to support up to approximately 200,000 patient cell units.
- The platform is designed for centralized processing with decentralized access, long-term cell preservation, and integration with longevity medicine, supported by partners like Guangdong Wanhai Cell Biotechnology Co., Ltd. and Shunfeng Cold Chain Logistics Co., Ltd. for logistics and clinical access.
Dec 30, 2025, 9:30 PM
EUDA Launches Stem Cell Therapy Platform and Shenzhen Clinic
EUDA
Product Launch
New Projects/Investments
M&A
- EUDA Health Holdings Limited is accelerating its longevity and regenerative medicine strategy with the launch of a comprehensive stem cell therapy platform and the establishment of its first clinic in Shenzhen, China.
- The company is upgrading Shenzhen Inno Immune Co. Ltd.'s cGMP facility in Shenzhen to create a state-of-the-art production and innovation center for stem cell treatments, integrating GO POSB Organoids Pte Ltd.'s iPSC technological platform and advanced stem cell technologies from Japanese partners.
- The new Shenzhen longevity clinic, established in partnership with KB International Ltd., will offer advanced stem cell and T-cell immunotherapies, personalized AI-guided life cycle management, and integrated Eastern, Western, and functional medicine.
- CEO Alfred Lim commented that this initiative positions EUDA to capitalize on the fast-growing longevity sector and operate at the frontier of healthcare.
Dec 23, 2025, 9:40 PM
EUDA Health Holdings Limited Enters Securities Purchase Agreement for Convertible Warrant
EUDA
- EUDA Health Holdings Limited entered into a Securities Purchase Agreement with Streeterville Capital, LLC on November 26, 2025, for the purchase of a convertible warrant.
- The warrant was purchased for $100,000 and is immediately exercisable into 2,000,000 newly-issued ordinary shares at an exercise price of $6.00 per share for ninety (90) days from the issuance date.
- During this 90-day "Cash Exercise Period," the company can initiate a "Forced Exercise" if the share's closing price is at or above $7.50 for five consecutive trading days and the cumulative trading volume is at least $1,500,000.
- Following the Cash Exercise Period, a two-week "Repurchase Period" allows the company to repurchase any remaining outstanding warrants for $0.0625 per Warrant Share; otherwise, a cashless exercise occurs, yielding one ordinary share for every ten outstanding Warrant Shares.
Dec 4, 2025, 10:17 PM
EUDA Subsidiary CK Health Plus Secures Malaysia Direct Selling License
EUDA
Product Launch
New Projects/Investments
- EUDA Health Holdings Limited's wholly-owned subsidiary, CK Health Plus Sdn. Bhd., secured a Direct Selling License (AJL 932509) from the Malaysian Ministry of Domestic Trade and Cost of Living on October 20, 2025.
- This license permits CK Health Plus to compliantly conduct direct selling and multi-level marketing operations for wellness products across Malaysia.
- The company plans to leverage this approval to accelerate the nationwide rollout of Bioenergy Capsule Centers and expand EUDA Helixé supplement distribution in Malaysia and Singapore.
Oct 20, 2025, 8:30 PM
EUDA Health Holdings Ltd. Reports Half-Year 2025 Financial Results and Going Concern Uncertainty
EUDA
Earnings
Legal Proceedings
M&A
- EUDA Health Holdings Ltd. reported a significant increase in total revenue by 60.2% to $3,057,323 for the six months ended June 30, 2025, compared to $1,908,048 for the same period in 2024, while also reducing its net loss by 92.9% to $(1,201,696) from $(16,832,947) in the prior year period.
- The company's management has determined there is substantial doubt about its ability to continue as a going concern within one year due to recurring losses from operations and negative cash flows, and is actively seeking additional financing.
- A new revenue stream from holistic wellness consumer products and services, totaling $893,785 for the six months ended June 30, 2025, was introduced following the acquisition of Fortress Cove in May 2024.
- EUDA successfully had a statutory demand for US$138,202.66 in alleged legal fees set aside by the British Virgin Islands Court on May 1, 2025.
Oct 1, 2025, 8:31 PM
EUDA Health Holdings Signs LOI for Potential Acquisition of Chemokine Pte Ltd
EUDA
M&A
- EUDA Health Holdings Limited signed a Letter of Intent (LOI) on August 28, 2025, to potentially acquire Chemokine Pte Ltd.
- The LOI grants EUDA an exclusivity period of at least 120 days to conduct due diligence on Chemokine, during which Chemokine will not engage in similar discussions with other entities.
- Chemokine is a Singapore-based biotech company focused on molecular supplements and gene modulating formulations, including Euda Helixé, a next-generation immune health supplement for which EUDA already holds exclusive worldwide distribution rights.
Aug 28, 2025, 8:30 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more